Scinai Immunotherapeutics (SCNI) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
VivoSim Labs is the larger company by market cap ($3.0 million vs $1.6 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCNI | VIVS |
|---|---|---|
| Share price | $1.18 | $0.1801 |
| Market cap | $1.60M | $2.99M |
| 1-day change | -2.48% | +1.64% |
| P/E ratio (TTM) | 0.04 | — |
| EPS (TTM) | $28.07 | $-4.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.65 | $3.40 |
| 52-week low | $1.06 | $0.1681 |
| Distance from 52-week high | -92.46% | -94.70% |
| Average volume | 1.10M | 5.84M |
| Shares outstanding | 1.35M | 16.59M |
| Employees | 45 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
SCNI vs VIVS FAQ
Which is bigger, Scinai Immunotherapeutics or VivoSim Labs?
VivoSim Labs (VIVS) is larger, with a market capitalization of $2.99M compared with $1.60M for Scinai Immunotherapeutics (SCNI).
Are Scinai Immunotherapeutics and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.